A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors
RMC-6291-101
Phase 1 other active
Quick answer
A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors for Participants with Advanced KRASG12C-Mutated Solid Tumors is a Phase 1 program (other) at Revolution Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Revolution Medicines
- Indication
- Participants with Advanced KRASG12C-Mutated Solid Tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active